Jazz Pharmaceuticals

1Exits tracked$820mDisclosed value$820mMedian price0Acquihires

Photo: Unknown / Wikimedia Commons, CC BY 4.0

Jazz Pharmaceuticals to buy Actio Biosciences for $820 million upfront

Jazz is paying for one drug: ABS-1230, an oral pill for a rare childhood epilepsy with no approved treatment. Actio's other programs will be spun out into a new company in which Jazz takes a minority stake.

Price$820mRaised$121mLast stageSeries BBuyer typeCorporate

Latest in Jazz PharmaceuticalsMore stories here soon.

All Jazz Pharmaceuticals exitsOpen tracker →

10 AugJazz Pharmaceuticals → Actio BiosciencesSan Diego · Series B · raised $121m$820m$250m–1bn